
ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair June 23, 2022






cdc.gov/coronavirus

Trends in number of COVID-19 cases in the United States among persons of <u>all ages</u>


Daily Trends in Number of COVID-19 Cases in The United States Reported to CDC




Source: COVID Data Tracker, https://covid.cdc.gov/covid-data-tracker/#trends dailytrendscases. Accessed 6/21/2022

Daily Trends in Number of COVID-19 Deaths, United States

Daily Trends in Number of COVID-19 Deaths in The United States Reported to CDC




Rates of COVID-19 deaths by vaccination status in people ages ≥5 years, United States, April 4, 2021—April 2, 2022



Unvaccinated people ages ≥5 years had **10X** the risk of dying from COVID-19 through March compared to people vaccinated with at least the primary series.


Percentage of children and adolescents who received at least one dose of the COVID-19 vaccine over time



Current recommendations for COVID-19 vaccines

 Only the Pfizer-BioNTech vaccine is currently authorized by FDA and recommended by CDC for use in children ages 5—17 years

COVID-19 Vaccination Schedule for Most People



FDA update

FDA authorizes the Moderna COVID-19 vaccine for children ages 6 through 17 years

- On June 16, 2022: FDA granted emergency use authorization (EUA) for:
 - A 2-dose Moderna COVID-19 vaccine primary series for administration to individuals ages
 6 through 17 years
 - Also authorized to provide a 3rd primary series dose to individuals ages 6 through 17 years with certain kinds of immunocompromise

ACIP COVID-19 vaccine Work Group Update:

June 18th Recommendations Following ACIP June 17-18, 2022

A **two-dose** Moderna COVID-19 vaccine series (25μg) is recommended for children ages **6 months –5 years**, under the EUA issued by FDA

Two doses of 25µg Moderna COVID-19 vaccine: ≥4 weeks between dose 1 and 2

A **three-dose** Pfizer-BioNTech COVID-19 vaccine series (3µg each) is recommended for children ages **6 months – 4 years**, under the EUA issued by FDA

Three doses of 3µg Pfizer-BioNTech COVID-19 vaccine: 3-8 weeks between dose 1 and 2; ≥8 weeks between dose 2 and 3

Agenda: Thursday June 23, 2022

Burden, prevalence, and trends of long-term sequelae of SARS-CoV2 Dr. Saydah (CDC)

Updates on safety of COVID-19 vaccines in children and adolescents Dr. Shimabukuro (CDC)

VaST assessment
 Dr. Talbot (ACIP, VaST Chair)

Safety and immunogenicity of Moderna 2-dose primary series
 Dr. Das (Moderna)

in children ages 6-17 years

Evidence to Recommendations Framework:
 Moderna COVID-19 vaccine in children & adolescents ages 6-17 years

PUBLIC COMMENT

VOTE

Moderna COVID-19 vaccine in children & adolescents ages 6-17 years

Work Group members

ACIP members

- Matthew Daley (chair)
- Beth Bell
- Grace Lee
- Keipp Talbot
- Oliver Brooks

Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang, Lucia Lee
- NIH: Chris Roberts
- IHS: Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

CDC Leads

- Sara Oliver
- Evelyn Twentyman

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O'Leary
- ACOG: Denise Jamieson (primary),
 Laura Riley (alternate)
- ACP: Jason Goldman
- ADS: Emily Kahn
- AGS: Ken Schmader
- AIM: Rob Shechter (primary),
 Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary),
 Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett, Paul Cieslak, Christine Hahn
 IDSA: Jeff Duchin (primary)

Liaisons, cont'd

- NACCHO: Matt Zahn (primary),
 Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary),Kelsey Young (alternate)
- NFID: Bill Schaffner (primary),
 Marla Dalton (alternate)
- NMA: Patricia Whitley-Williams
- SHEA: Marci Drees

Consultants


- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
- Hank Bernstein

CDC participants

- Sarah Meyer
- Evelyn Twentyman
- Tara Anderson
- Amy Blain
- Mary Chamberland
- Katherine Fleming-Dutra
- Monica Godfrey
- Susan Goldstein
- Stephen Hadler
- Elisha Hall
- Valerie Morelli
- Danielle Moulia
- Lauren Roper
- Edwin Shanley
- Megan Wallace

- JoEllen Wolicki
- Amanda Cohn
- Jessica MacNeil
- Elfriede Agyemang
- Karen Broder
- Allison Ciesla
- Kathleen Dooling
- Ashley Fowlkes
- Samuel Graitcer
- Rebecca Greco Kone
- Katherine Grusich
- Rita Helfand
- Terri Hyde
- Jefferson Jones
- Cynthia Jorgensen

- Andrew Kroger
- Ruth Link-Gelles
- Lauri Markowitz
- Kristen Nordlund
- Tamara Pilishvili
- José Romero
- Heather Scobie
- Tom Shimabukuro
- John Su
- Natalie Thornburg
- Melinda Wharton
- Ryan Wiegand
- Janet Wright
- Patricia Yu
- Yon Yu



For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

